Tara O Henderson1, Susan K Parsons2, Kristen E Wroblewski3, Lu Chen4, Fangxin Hong5, Sonali M Smith6, Jennifer L McNeer1, Ranjana H Advani7, Randy D Gascoyne8, Louis S Constine9, Sandra Horning10, Nancy L Bartlett11, Bijal Shah12, Joseph M Connors8, John I Leonard13, Brad S Kahl11, Kara M Kelly14, Cindy L Schwartz15, Hongli Li16, Jonathan W Friedberg9, Debra L Friedman17, Leo I Gordon18, Andrew M Evens2. 1. Department of Pediatrics, University of Chicago, Chicago, Illinois. 2. Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts. 3. Department of Public Health Sciences, University of Chicago, Chicago, Illinois. 4. Children's Oncology Group, Acadia, California. 5. Department of Biostatistics, Dana-Farber Cancer Institute, Boston, Massachusetts. 6. Department of Medicine, University of Chicago, Chicago, Illinois. 7. Department of Medicine, Stanford University, Palo Alto, California. 8. British Columbia Cancer Agency, Vancouver, British Columbia, Canada. 9. Departments of Radiation Oncology and Pediatrics, University of Rochester, Rochester, New York. 10. Genentech, San Francisco, California. 11. Washington University School of Medicine, St. Louis, Missouri. 12. Moffitt Cancer Center, Tampa, Florida. 13. Department of Medicine, Cornell Weill School of Medicine, New York, New York. 14. Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, New York. 15. Department of Oncology, Children's Hospital of Wisconsin, Milwaukee, Wisconsin. 16. Fred Hutchinson Cancer Research Center, Seattle, Washington. 17. Department of Pediatrics, Vanderbilt University, Nashville, Tennessee. 18. Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Abstract
BACKGROUND: There is no clear consensus between pediatric and adult providers about the treatment of adolescents and young adults (AYAs) with Hodgkin lymphoma (HL). METHODS: Failure-free survival (FFS) and overall survival (OS) were compared between 114 patients ages 17 to 21 years with HL who were treated on the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Intergroup adult E2496 study and 391 similarly patients ages 17 to 21 years with HL who were treated on the pediatric Children's Oncology Group (COG) AHOD0031 study. RESULTS: Comparing AYAs from the COG and E2496 studies, there were no significant differences in extralymphatic disease, anemia, or hypoalbuminemia. More AYAs in the E2496 trial had stage III and IV disease (63% vs 29%; P < .001) and B symptoms (63% vs 27%; P < .001), and fewer had bulk disease (33% vs 77%; P < .001). More AYAs on the COG trial received radiotherapy (76% vs 66%; P = .03), although in smaller doses. E2496 AYA The 5-year FFS and OS rates were 68% and 89%, respectively in the E2496 AYAs and 81% and 97%, respectively, in the COG AYAs, indicating a statistically superior compared in the COG AYAs (P = .001). In stratified multivariable analyses, E2496 AYAs had worse FFS than COG AYAs in all strata except patients who had stage I and II HL without anemia. Propensity score analysis (based on stage, anemia, and bulk disease) confirmed inferior FFS for E2496 AYAs compared with COG AYAs (P = .004). On the E2496 study, FFS was significantly divergent across age groups (P = .005), with inferior outcomes for those ages 17 to 21 years versus 22-44 years. There was no difference across age on the COG study. CONCLUSIONS: Younger AYA patients with HL appear to have better outcomes when treated on a pediatric trial than patients of similar age on an adult trial. Prospective studies examining these differences are warranted. Cancer 2018;124:136-44.
BACKGROUND: There is no clear consensus between pediatric and adult providers about the treatment of adolescents and young adults (AYAs) with Hodgkin lymphoma (HL). METHODS: Failure-free survival (FFS) and overall survival (OS) were compared between 114 patients ages 17 to 21 years with HL who were treated on the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Intergroup adult E2496 study and 391 similarly patients ages 17 to 21 years with HL who were treated on the pediatric Children's Oncology Group (COG) AHOD0031 study. RESULTS: Comparing AYAs from the COG and E2496 studies, there were no significant differences in extralymphatic disease, anemia, or hypoalbuminemia. More AYAs in the E2496 trial had stage III and IV disease (63% vs 29%; P < .001) and B symptoms (63% vs 27%; P < .001), and fewer had bulk disease (33% vs 77%; P < .001). More AYAs on the COG trial received radiotherapy (76% vs 66%; P = .03), although in smaller doses. E2496 AYA The 5-year FFS and OS rates were 68% and 89%, respectively in the E2496 AYAs and 81% and 97%, respectively, in the COG AYAs, indicating a statistically superior compared in the COG AYAs (P = .001). In stratified multivariable analyses, E2496 AYAs had worse FFS than COG AYAs in all strata except patients who had stage I and II HL without anemia. Propensity score analysis (based on stage, anemia, and bulk disease) confirmed inferior FFS for E2496 AYAs compared with COG AYAs (P = .004). On the E2496 study, FFS was significantly divergent across age groups (P = .005), with inferior outcomes for those ages 17 to 21 years versus 22-44 years. There was no difference across age on the COG study. CONCLUSIONS: Younger AYA patients with HL appear to have better outcomes when treated on a pediatric trial than patients of similar age on an adult trial. Prospective studies examining these differences are warranted. Cancer 2018;124:136-44.
Authors: Debra L Friedman; Lu Chen; Suzanne Wolden; Allen Buxton; Kathleen McCarten; Thomas J FitzGerald; Sandra Kessel; Pedro A De Alarcon; Allen R Chen; Nathan Kobrinsky; Peter Ehrlich; Robert E Hutchison; Louis S Constine; Cindy L Schwartz Journal: J Clin Oncol Date: 2014-10-13 Impact factor: 44.544
Authors: Jamie E Flerlage; Kara M Kelly; Auke Beishuizen; Steve Cho; Pedro A De Alarcon; Ute Dieckmann; Richard A Drachtman; Bradford S Hoppe; Scott C Howard; Sue C Kaste; Regine Kluge; Lars Kurch; Judith Landman-Parker; Jocelyn Lewis; Michael P Link; Kathleen McCarten; Angela Punnett; Dietrich Stoevesandt; Stephan D Voss; William Hamish Wallace; Christine Mauz-Körholz; Monika L Metzger Journal: Pediatr Blood Cancer Date: 2017-01-18 Impact factor: 3.167
Authors: Kara M Kelly; David Hodgson; Burton Appel; Lu Chen; Peter D Cole; Terzah Horton; Frank G Keller Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Christine Mauz-Körholz; Monika L Metzger; Kara M Kelly; Cindy L Schwartz; Mauricio E Castellanos; Karin Dieckmann; Regine Kluge; Dieter Körholz Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Kristie A Blum; Frank G Keller; Sharon Castellino; Anh Phan; Christopher R Flowers Journal: Br J Haematol Date: 2018-08-10 Impact factor: 6.998
Authors: Anni Young Lundgaard; Lisa Lyngsie Hjalgrim; Laura Ann Rechner; Michael Lundemann; N Patrik Brodin; Morten Joergensen; Lena Specht; Maja Vestmoe Maraldo Journal: Strahlenther Onkol Date: 2020-12-09 Impact factor: 3.621
Authors: Justine M Kahn; Qinglin Pei; Debra L Friedman; Joel Kaplan; Frank G Keller; David Hodgson; Yue Wu; Burton E Appel; Smita Bhatia; Tara O Henderson; Cindy L Schwartz; Kara M Kelly; Sharon M Castellino Journal: Lancet Haematol Date: 2022-01 Impact factor: 18.959
Authors: Eugene Suh; Kayla L Stratton; Wendy M Leisenring; Paul C Nathan; Jennifer S Ford; David R Freyer; Jennifer L McNeer; Wendy Stock; Marilyn Stovall; Kevin R Krull; Charles A Sklar; Joseph P Neglia; Gregory T Armstrong; Kevin C Oeffinger; Leslie L Robison; Tara O Henderson Journal: Lancet Oncol Date: 2020-02-14 Impact factor: 41.316